Enhanced Timeliness and Co-Administration of Meningitis B Vaccination in Children: Impact of Funding in Valencian Community, Spain
Juan Juaneda,
Pablo Estrella-Porter,
Carolina Blanco-Calvo,
Alejandro Orrico-Sánchez,
José Antonio Lluch-Rodrigo,
Eliseo Pastor-Villalba
Affiliations
Juan Juaneda
Directorate-General for Public Health, Conselleria de Sanitat, 46010 Valencia, Spain
Pablo Estrella-Porter
Directorate-General for Public Health, Conselleria de Sanitat, 46010 Valencia, Spain
Carolina Blanco-Calvo
Directorate-General for Public Health, Conselleria de Sanitat, 46010 Valencia, Spain
Alejandro Orrico-Sánchez
Vaccines Research Unit, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), 46017 Valencia, Spain
José Antonio Lluch-Rodrigo
Directorate-General for Public Health, Conselleria de Sanitat, 46010 Valencia, Spain
Eliseo Pastor-Villalba
Directorate-General for Public Health, Conselleria de Sanitat, 46010 Valencia, Spain
Public funding of vaccines may enhance vaccination rates, co-administration, and timeliness. The impacts of including the serogroup B meningococcus vaccine (MenB) into the national immunisation schedule on vaccination rates, co-administration rates, and timeliness were assessed using a population-based pre-funding (2022) and post-funding (2023) study design. MenB vaccination rates improved after funding and were in line with previously funded vaccines. Co-administration rates also increased significantly. Timely administration increased, protecting children at an early age. Public funding has a positive impact on vaccine accessibility and early protection. Consistent population characteristics highlight the role of funding.